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ABSTRACT
Background: The Respiratory Symptoms Questionnaire (RSQ) is a novel, four-item patient-reported
diagnosis-agnostic tool designed to assess the frequency of respiratory symptoms and their impact on
activity, without specifying a particular diagnosis. Our objective was to examine its validity in patients with
asthma and/or chronic obstructive pulmonary disease (COPD).
Methods: Baseline data were randomly sampled from patients who completed the RSQ in the NOVELTY
study (ClinicalTrials.gov: NCT02760329). The total sample (n=1530) comprised three randomly selected
samples (n=510 each) from each physician-assigned diagnostic group (asthma, asthma+COPD and COPD).
The internal consistency and structural validity of the RSQ were evaluated using exploratory and
confirmatory factor analyses; psychometric performance was observed using Classical Test Theory and Item
Response Theory analyses.
Results: For the total sample, the mean±SD RSQ score was 5.6±4.3 (range 0–16). Irrespective of diagnosis,
the internal consistency of items was uniformly adequate (Cronbach’s α=0.76–0.80). All items had high
factor loadings and structural characteristics of the measure were invariant across groups. Using the total
sample, RSQ items informatively covered the θ score range of –2.0 to 2.8, with discrimination coefficients
for individual items being high to very high (1.7–2.6). Strong convergent correlations were observed
between the RSQ and the St George’s Respiratory Questionnaire (0.77, p<0.001).
Conclusions: The RSQ is a valid, brief, patient-reported tool for assessing respiratory symptoms in patients
across the whole spectrum of asthma and/or COPD, rather than using different questionnaires for each
diagnosis. It can be used for monitoring respiratory symptoms in clinical practice, clinical trials and real-world
studies.
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Respiratory symptoms are common and troublesome across the spectrum of obstructive lung disease, and
are integral to the definitions of asthma and chronic obstructive pulmonary disease (COPD) [1, 2]. The
presence of respiratory symptoms among current or ex-smokers with preserved lung function may also
indicate a greater risk of exacerbations than among those who are asymptomatic [3]. However, many
questionnaires that assess the frequency, impact or control of respiratory symptoms are designed
specifically for patients with a confirmed diagnosis of either asthma or COPD [1, 2]. Questionnaires such
as the Asthma Control Questionnaire (ACQ) and Asthma Control Test (ACT) provide composite scores of
asthma symptom control [4]; however, neither is applicable for use in other obstructive lung diseases due
to the inclusion of questions specifically referencing patients’ asthma [5, 6]. Furthermore, for patients with
COPD, there are no similar symptom control questionnaires.
Three general respiratory symptom domains (breathing, coughing and chest symptoms) have been identified
as common to both asthma and COPD [7–9]. These have been confirmed in qualitative concept elicitation
patient interviews as part of two projects to develop diagnosis-specific symptom diary measures for asthma
and COPD: the Asthma Daily Symptoms Diary, with a corresponding diary for night symptoms, and the
EXACT (EXAcerbations of Chronic obstructive pulmonary disease Tool) for Respiratory Symptoms (E-RS:
COPD) diary [7–9]. Some questions about general respiratory symptoms are included in several
health-related quality-of-life questionnaires validated for use in asthma (e.g. the Asthma Quality of Life
Questionnaire [10, 11]) or COPD (e.g. the Clinical COPD Questionnaire [12] and COPD Assessment
Test [13]), but only two health status questionnaires have been validated for use in both conditions: the
Airways Questionnaire 20 (AQ20) [14, 15] and St George’s Respiratory Questionnaire (SGRQ) [11, 16].
However, there is no brief questionnaire for assessment of respiratory symptoms across asthma and
COPD. Given the well-recognised overlap between asthma and COPD [17], and the increasing interest in
developing more specific classifications of obstructive lung disease [18], there is a need for brief,
“diagnosis-agnostic” (i.e. non-disease-specific) measures of respiratory symptoms in patients with asthma
and/or COPD, so that the same tool can be used regardless of patients’ diagnostic labels. A brief
diagnosis-agnostic tool would also be useful in clinical practice, especially in primary care, for monitoring
patients with asthma and/or COPD, or who have not yet received a specific diagnosis.
The aim of this article is to describe the development of the Respiratory Symptoms Questionnaire (RSQ),
and to assess its psychometric validity in patients with diagnoses of asthma and/or COPD.
Methods
Development of the RSQ
The RSQ was developed as a simple tool for use in both primary and specialist care settings to assess the
frequency of respiratory symptoms and their impact on the patient’s activity, without requiring a specific
diagnostic label. Like the ACQ and ACT, the content of the RSQ was conceptually based on clinical
guidelines for assessment of symptoms of asthma and of COPD [1, 2], i.e. the frequency of symptoms, and
the extent to which they impact on the patient’s activity. Furthermore, key symptoms assessed by the RSQ
reflect the three symptom domains that are common to both asthma and COPD (breathing, coughing and
chest symptoms).
The RSQ comprises four questions (items 1–4) related to respiratory symptoms and their impact on the
patient’s activity: 1) frequency of symptoms of daytime shortness of breath, wheezing, coughing and/or
chest tightness; 2) frequency of rescue (reliever) inhaler use in response to these symptoms; 3) degree of
activity limitation due to these symptoms; and 4) frequency of night-time awakenings due to these
symptoms (each over the previous 4 weeks) (figure 1). This is a similar structure to the Global Initiative
for Asthma symptom control criteria [1]. RSQ score (range 0–16) is the sum score of the four items
(scored 0–4), with higher scores indicative of worse symptoms. For valid scoring, all four items must be
completed, otherwise RSQ scores are treated as missing.
Cognitive debriefing of RSQ items and response options was performed in patients with asthma (n=5) or
COPD (n=5). RWS Life Sciences (East Hartford, CT, USA) employed a qualified recruiter to enlist
potential patients in the USA and selected a convenience sample of patients who were native English
speakers or literate and fluent in English. RWS Life Sciences selected a trained interviewer to conduct
cognitive interviews; patients were guided through the RSQ and asked questions designed to capture their
understanding and ensure that they could follow the instructions clearly. If patients expressed difficulty
understanding, the interviewer asked questions to determine the reason. Overall, the patients were able to
understand and use the RSQ; therefore, no changes were made to RSQ items or response options. Experts
in linguistic validation from RWS Life Sciences provided harmonised translations of the original English
questions into 19 languages.
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Psychometric validation of the RSQ
RSQ validation was conducted within a larger study: NOVELTY (a NOVEL observational longiTudinal
studY; ClinicalTrials.gov: NCT02760329), which is a global, prospective, 3-year observational study of
approximately 12000 patients from 19 countries with a physician-assigned diagnosis or suspected
diagnosis of asthma and/or COPD [19]. The aim of the present analysis was to use baseline data randomly
sampled from NOVELTY to evaluate the reliability and validity of the RSQ as a measure of respiratory
symptoms in patients with obstructive lung disease.
The NOVELTY study design has been reported previously [19]. Enrolment was stratified by
physician-assigned diagnosis (asthma, both asthma and COPD (asthma+COPD) or COPD) and
physician-assessed severity (mild, moderate or severe). No diagnostic or severity criteria were pre-specified
when determining eligibility; diagnosis and assessment of severity were therefore decided by the physician.
For patients with asthma+COPD, severity was allocated as the higher of the two severity categories
assigned by the physician for their asthma and their COPD.
Patients in the NOVELTY study completed several patient-reported outcome (PRO) tools (by web-based
platform or telephone) at the baseline visit or up to 21 days later [19]. Physicians were not aware of the
responses to the RSQ or other PROs when assessing severity.
1. In the past 4 weeks, how often have you had shortness of breath, wheezing,
 coughing and/or chest tightness during the day?
Scoring
Not at all
One or two days a week
Three to six days a week
Once every day






2. In the past 4 weeks, how often did you use a rescue inhaler (quick relief inhaler)
 in response to shortness of breath, wheezing, coughing and/or chest tightness?
Not at all
One or two days a week
Three to six days a week
Once or twice every day






3. In the past 4 weeks, how limited were your activities as a result of shortness
 of breath, wheezing, coughing and/or chest tightness?










4. In the past 4 weeks, how often did you wake up at night due to shortness of
 breath, wheezing, coughing and/or chest tightness?
Not at all
One or two nights in the past 4 weeks
One night a week
Two or three nights a week






FIGURE 1 The Respiratory Symptoms Questionnaire (RSQ), response options and scoring. Responses to each
of the four RSQ questions (items 1–4) are scored 0–4, with higher scores indicative of more frequent or worse
symptoms. Total score ranges from 0 to 16. The RSQ is available for free use for legitimate scientific and
clinical care reasons; AstraZeneca retains licensing rights through RWS Life Sciences (for further details,
contact: astrazeneca@rws.com).
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Validation analysis design
This validation analysis used data obtained from NOVELTY patients’ responses to the RSQ, SGRQ,
EuroQol Visual Analogue Scale (EQ VAS) and modified Medical Research Council (mMRC) dyspnoea
scale (completed by all patients) and ACT (completed by patients with asthma or asthma+COPD).
Baseline data were randomly sampled from patients who had valid RSQ data (no missing responses) and
had physician-assigned diagnoses of asthma, asthma+COPD or COPD. The total sample (n=1530)
comprised three groups of 510 patients randomly selected from these diagnostic groups (asthma n=510
out of 3613, asthma+COPD n=510 out of 819 and COPD n=510 out of 2343). Sample sizes were selected
to adequately power key psychometric analyses (supplementary material). Simple random sampling was
expected to provide a balanced representation of severity categories (mild, moderate and severe) that was
reflective of the NOVELTY study.
Objectives
This analysis aimed to evaluate the reliability and validity of the RSQ as a diagnosis-agnostic (i.e.
non-disease-specific) measure of respiratory symptoms in patients with physician-assigned asthma and/or
COPD.
Primary objectives
The primary objectives were to: 1) assess the internal consistency, unidimensionality and structural validity
of the RSQ to evaluate the coherence of the RSQ measure, and assess the structural and measurement
invariance of the RSQ across diagnostic groups using confirmatory factor analysis; 2) examine the linearity
of RSQ item response associated with physician-assessed severity categories using Classical Test Theory;
3) examine RSQ item information functions, to evaluate whether similar profiles were found across
diagnostic groups and evaluate RSQ item response characteristics over the observed range of criterion
metrics; and 4) examine the differential performance of RSQ items to sex and physician-assigned diagnosis
using Item Response Theory, to determine the equivalence of RSQ item function for groups of interest.
Secondary objective
The secondary objective was to evaluate the construct validity of the RSQ. This included the convergent
validity with measures expected to be related (e.g. SGRQ, EQ VAS, mMRC dyspnoea scale and
physician-assessed severity) and the divergent validity with measures expected to be unrelated or weakly
related (e.g. spirometry assessments). Additional analyses assessed the known-groups validity of the RSQ
based on known-group characteristics (e.g. physician-assessed severity).
Psychometric analyses
The psychometric performance of the RSQ was examined using two distinct statistical methods. The first
set of methods examined the RSQ structural and measurement characteristics based on Classical Test
Theory. Classical methods describe score distributions as being composed of both meaningful (true) score
variance and random variation of scores (error). These analyses focused on the structural characteristics of
the measure and the incremental difference in physician-assessed severity (mild, moderate or severe)
observed at each RSQ response level. A second set of analyses was based on modern test theory (Item
Response Theory) and used a graded response model to evaluate measurement performance of RSQ items
based on the probability of endorsement of scaling options at different RSQ response thresholds along the
severity/impact continuum. These analyses were performed using IRTPRO [20]. More detailed
methodology for each analytical objective is provided in the supplementary material.
Results
Patient demographics and clinical characteristics
Patients with physician-assigned asthma were younger than those with asthma+COPD and COPD (mean
age 52.7 versus 65.6 and 67.3 years, respectively) and a higher proportion were female (64.1% versus 45.1%
and 38.4%, respectively) (table 1).
More patients had mild asthma (36.9%) than mild COPD (23.9%) and more patients had severe COPD
(46.7%) than severe asthma (26.7%) (supplementary table S1).
Patients with asthma had lower mean SGRQ scores versus those with asthma+COPD or COPD (table 1);
these patterns were also observed across each severity category (supplementary table S1). Patients with
asthma also had a higher mean post-bronchodilator forced expiratory volume in 1 s % predicted versus those
with asthma+COPD or COPD overall (table 1) and across severity categories (supplementary table S1).
The mean±SD RSQ score in the total sample was 5.6±4.3 out of a maximum of 16, with lower scores
among patients with asthma versus asthma+COPD or COPD (table 1).
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Structural validity
Differences in the dimensional structure of the RSQ between diagnostic groups were minimal and the
internal consistency of items was uniformly adequate (Cronbach’s α>0.7; asthma α=0.80, asthma+COPD
α=0.79, COPD α=0.76 and total sample α=0.79). Additionally, all items had high factor loadings on
exploratory factor analysis and thereby all contributed to the explained variance of a one-factor solution in a
very similar way across all diagnostic groups (table 2). Using random samples, the structure of the RSQ and
the measurement estimates it provided were invariant across diagnostic groups (supplementary table S2).
Linearity of item response
The response options for RSQ items were in the expected sequential order and all items exhibited linear
relationships with physician-assessed severity, both in the total sample (figure 2) and in each
physician-assigned diagnostic group (supplementary figure S1). There was also a linear relationship
between RSQ total scores and severity categories in the total sample (figure 3). However, 9.8% (n=17 out
of 174) of patients with an RSQ score of 0 for the previous 4 weeks had physician-assessed severity of
TABLE 1 Patient demographics and clinical assessments by physician-assigned diagnosis
Asthma Asthma+COPD COPD Total sample
Patients 510 510 510 1530
Age years 52.7±15.5 65.6±9.7 67.3±9.6 61.8±13.6
Sex
Female 327 (64.1) 230 (45.1) 196 (38.4) 753 (49.2)
Male 183 (35.9) 280 (54.9) 314 (61.6) 777 (50.8)
Ethnicity
African-American 22 (4.3) 19 (3.7) 21 (4.1) 62 (4.1)
Caucasian 371 (72.7) 395 (77.5) 424 (83.1) 1190 (77.8)
North East Asian 38 (7.5) 24 (4.7) 5 (1.0) 67 (4.4)
South East Asian 8 (1.6) 3 (0.6) 3 (0.6) 14 (0.9)
Other 71 (13.9) 69 (13.5) 57 (11.2) 197 (12.9)
Time since diagnosis years
Patients with non-missing data 324 (63.5) 379 (74.3) 363 (71.2) 1066 (69.7)
Mean±SD 15.4±16.1 14.7±16.8 7.0±6.6 12.3±14.4
Physician-assessed severity#
Mild 188 (36.9) 90 (17.6) 122 (23.9) 400 (26.1)
Moderate 186 (36.5) 223 (43.7) 150 (29.4) 559 (36.5)
Severe 136 (26.7) 197 (38.6) 238 (46.7) 571 (37.3)
Post-BD FEV1 % pred
Patients with non-missing data 408 (80.0) 432 (84.7) 417 (81.8) 1257 (82.2)
Mean±SD 85.6±19.7 66.7±21.7 58.3±22.3 70.1±24.1
SGRQ total score¶
Patients with non-missing data 507 (99.4) 508 (99.6) 507 (99.4) 1522 (99.5)
Mean±SD 29.8±21.0 40.2±22.4 41.9±22.0 37.3±22.4
mMRC dyspnoea scale grade+
Patients with non-missing data 490 (96.1) 496 (97.3) 498 (97.6) 1484 (97.0)
Mean±SD 0.9±0.9 1.5±1.0 1.7±1.1 1.4±1.1
ACT score§
Patients with non-missing data 495 (97.1) 454 (89.0) NA 949 (62.0)
Mean±SD 19.6±4.5 17.6±5.1 NA 18.6±4.9
RSQ scoreƒ
Patients with non-missing data 510 (100.0) 510 (100.0) 510 (100.0) 1530 (100.0)
Mean±SD 4.4±3.8 6.4±4.4 6.0±4.3 5.6±4.3
Data are presented as n, mean±SD or n (%). COPD: chronic obstructive pulmonary disease; BD:
bronchodilator; FEV1: forced expiratory volume in 1 s; SGRQ: St George’s Respiratory Questionnaire;
mMRC: modified Medical Research Council; ACT: Asthma Control Test; NA: not applicable; RSQ:
Respiratory Symptoms Questionnaire. #: for patients with asthma+COPD, severity was allocated as the
higher of the two severity categories assigned by the physician for their asthma and their COPD; ¶: range
0–100; +: range 0–4; §: range: 5–25; ƒ: valid scoring of the RSQ requires that all items have been
completed and the sum score (range 0–16) is used (the total scores of individuals with missing values for
any item were treated as missing and only patients with valid RSQ scores were randomly selected for this
analysis).
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“severe” (asthma n=4 out of 83, asthma+COPD n=5 out of 41 and COPD n=8 out of 50) and 8.3% (n=1
out of 12) of patients with an RSQ score of 16 had “mild” severity.
Item response characteristics
Based on Item Response Theory methods, RSQ items informatively covered the difficulty Item Response
Theory score range (θ). Here, “difficulty” refers to the location of a response on the symptom frequency
and degree of activity limitation continuum (i.e. θ) as measured by the RSQ. Collectively across the total
sample, θ lay between −2.0 and 2.8, and at least −1.6 to >2.8 for each physician-assigned diagnostic group,
indicating that the RSQ provides similar information across diagnostic groups (supplementary figure S2).
The discrimination coefficients for individual items were high to very high (range 1.7–2.6) and in line with
items that provide a broad coverage of the response continuum (i.e. RSQ assessment dimension) [21]. The
measurement precision estimates for the RSQ were adequate (>0.8), ranging from 0.79 to 0.81 [22].
Differential item function
The absence of differential item functioning (a measure of the differences in the way items behave between
discrete groups) was used to evaluate the equivalence of RSQ item function for groups of interest. No
uniform differential item functioning was observed (supplementary table S3). Non-uniform differential
item functioning was observed on one or two items between physician-assigned diagnostic groups (asthma
versus COPD: items 3 and 4; asthma versus asthma+COPD: item 4; and COPD versus asthma+COPD:
items 2 and 3) and on item 1 for sex (supplementary table S3).
Construct validity
Convergent correlations between the RSQ and clinical variable assessments were highest for a health status
measure (SGRQ) and ACT score (for patients with asthma), but were lower for a general health measure
(EQ VAS), a single-symptom measure (mMRC dyspnoea scale) and physician-assessed severity (table 3).
Divergent correlations were observed for spirometry measures (table 3).
Known-groups validity
Table 4 presents RSQ scores by physician-assessed severity. Significance tests using standardised mean
differences between groups showed that the RSQ differentiated all categories of severity within the total
sample and the COPD group, as well as between mild or moderate versus severe categories within the
asthma and asthma+COPD groups.
TABLE 2 Exploratory factor analysis using principal components factoring
Asthma Asthma+COPD COPD Total sample
Patients 510 510 510 1530
Factor loadings for RSQ items
1# 0.800 0.819 0.798 0.812
2¶ 0.760 0.761 0.734 0.758
3+ 0.814 0.820 0.806 0.817
4§ 0.817 0.757 0.744 0.770
Eigenvaluesƒ
Factor 1 2.55 2.49 2.38 2.49
Factor 2 0.55 0.57 0.60 0.55
Variance explained % 63.7 62.4 59.4 62.4
Data are presented as n, unless otherwise stated. COPD: chronic obstructive pulmonary disease; RSQ:
Respiratory Symptoms Questionnaire. #: question 1 (“In the past 4 weeks, how often have you had
shortness of breath, wheezing, coughing and/or chest tightness during the day?”); ¶: question 2 (“In the
past 4 weeks, how often did you use a rescue inhaler (quick relief inhaler) in response to shortness of
breath, wheezing, coughing and/or chest tightness?”); +: question 3 (“In the past 4 weeks, how limited
were your activities as a result of shortness of breath, wheezing, coughing and/or chest tightness?”);
§: question 4 (“In the past 4 weeks, how often did you wake up at night due to shortness of breath,
wheezing, coughing and/or chest tightness?”); ƒ: one factor was retained for each analysis based on a
factor retention criteria of eigenvalue ⩾1.00 (a second factor did not meet this threshold and there were
no items with split loadings in a two-factor solution).
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Discussion
In this investigation of the psychometric properties of the RSQ (a simple, new respiratory symptoms
questionnaire independent of diagnosis) the internal consistency and scale measurement structure of the
tool were consistent across patients with physician-assigned diagnoses of asthma and/or COPD. The RSQ
correlated well with the SGRQ, which, although a measure of health status in asthma and in COPD,
includes multiple items addressing patient-reported respiratory symptoms and their impact. Strong
correlations were also observed between the RSQ and ACT (for patients with asthma), which includes
similar questions, also over 4 weeks. By comparison, weaker correlations were observed between the RSQ
and mMRC dyspnoea scale (which assesses a single symptom, dyspnoea, without a defined time period),
and with overall health status assessed by EQ VAS. Divergent correlations were observed with spirometry
measures, consistent with other studies of respiratory symptom measures that have shown discordance
between subjective and objective measures [23–26].
This evaluation was conducted among patients from the NOVELTY study [19], a large observational study
that includes patients with physician-assigned diagnoses (or suspected diagnoses) of asthma,
asthma+COPD and COPD [27]. Across all diagnoses, mean RSQ scores were greater with higher
physician-assessed severity and statistically differentiated patients with severe disease from those with mild
or moderate disease. Although differences in RSQ scores between mild and moderate disease in patients




























































































































FIGURE 2 Distribution of physician-assessed severity (mild, moderate or severe) in the total sample for
Respiratory Symptoms Questionnaire (RSQ) items, by response score: a) item 1 (frequency of daytime
symptoms), b) item 2 (frequency of rescue inhaler use), c) item 3 (degree of activity limitation) and d) item 4
(frequency of night-time awakenings due to symptoms). The total sample (n=1530) comprised patients with
physician-assigned diagnoses of asthma (n=510), asthma+COPD (n=510) and COPD (n=510). See figure 1 for
full details of the RSQ questions and response options. Physicians were not aware of a patient’s RSQ
responses when they assigned the severity category. Percentages within columns may not total 100% due to
rounding.
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such as the ACT, SGRQ and mMRC dyspnoea scale; as such, it may reflect a lack of standardisation of
severity assessment among physicians, as opposed to the performance of the RSQ. For example, although
all RSQ items and RSQ total score exhibited an overall linear relationship with severity, ∼10% of patients
with RSQ scores of 0 had a severity classification of “severe”. This suggests that respiratory symptoms may
































































































FIGURE 3 Distribution of physician-assessed severity (mild, moderate or severe) in the total sample, by Respiratory Symptoms Questionnaire
(RSQ) score. The total sample (n=1530) comprised patients with physician-assigned diagnoses of asthma (n=510), asthma+COPD (n=510) and
COPD (n=510). Percentages within columns may not total 100% due to rounding.
TABLE 3 Convergent and divergent correlations between clinical assessments and total
Respiratory Symptoms Questionnaire score
Asthma Asthma+COPD COPD Total sample
Patients 510 510 510 1530
Convergent correlations
SGRQ total score 0.72*** 0.77*** 0.77*** 0.77***
ACT score −0.84*** −0.84*** NA NA
EQ VAS −0.43*** −0.54*** −0.51*** −0.52***
mMRC dyspnoea scale grade 0.41*** 0.47*** 0.44*** 0.47***
Physician-assessed severity# 0.31*** 0.33*** 0.31*** 0.34***
Divergent correlations
Post-BD FEV1 % pred −0.29*** −0.37*** −0.27*** −0.36***
Post-BD FVC % pred −0.22*** −0.34*** −0.23*** −0.29***
Post-BD FEV1/FVC −0.20*** −0.15** −0.16** −0.23***
Post-BD FEF25–75% % pred −0.18** −0.07 0.00 −0.14***
Data are presented as n, unless otherwise stated. COPD: chronic obstructive pulmonary disease; SGRQ:
St George’s Respiratory Questionnaire; ACT: Asthma Control Test; NA: not applicable; EQ VAS: EuroQol
Visual Analogue Scale; mMRC: modified Medical Research Council; BD: bronchodilator; FEV1: forced
expiratory volume in 1 s; FVC: forced vital capacity; FEF25–75%: forced expiratory flow at 25–75% of FVC.
For each variable, analyses were performed for patients with non-missing data; patient numbers differed
for each variable based on data availability. Correlation coefficients >0.7 are regarded as strong, 0.4–0.7 as
moderate and <0.4 as weak. #: disease severity was categorised as mild, moderate or severe, as assigned
by physician judgement (in order to calculate correlation coefficients, severity categories were assigned a
numerical value: mild=1, moderate=2 and severe=3). **: p<0.01; ***: p<0.001.
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the weak convergent correlations observed between the RSQ and physician-assessed severity. Physicians
may have considered other factors such as comorbidities, treatment level (including biologic therapy) and
exacerbation history. Currently, guidelines for assessing asthma severity advise identifying the patient’s
minimum effective treatment, which is not possible in an observational study [1], and there are no
standardised recommendations for classifying COPD severity (except for severity of airflow limitation) [2].
Of note, when physicians classified severity they were not aware of patient responses to the RSQ or other
PROs (e.g. ACT and SGRQ), with the exception of the mMRC dyspnoea scale grades, which were entered
into electronic case report forms during visits.
Strengths of this analysis include the large real-world patient population recruited from active clinical
practices in both primary and secondary care, the inclusion of patients with physician-assigned asthma,
asthma+COPD and COPD, and the systematic recording of other relevant PROs. Within this broad
context, the RSQ performed well using physician-assessed severity and various other criterion measures
used in clinical practice. Limitations include that, like the ACT and ACQ, the content of the RSQ was
conceptually based on clinical guidelines for assessing symptoms (primarily the extension of asthma
symptom control criteria [1] to COPD [2] for the RSQ), so patient input into the development of the RSQ
was limited to cognitive debriefing. Cognitive debriefing should be repeated for translated versions, given
the variation in language about breathlessness between different ethnic groups [28]. An equal number of
patients within each diagnostic label was randomly sampled from the NOVELTY population, so patients
with asthma+COPD were relatively oversampled in this analysis (33%) versus the whole NOVELTY
population (12%) [29]. This may affect the generalisability of results involving the total sample and
asthma+COPD group. Future longitudinal data are required to further explore the performance of the
RSQ, particularly to assess predictive validity, whether it reflects changes in respiratory symptoms over
time and to provide estimates of a minimal clinically important difference.
Overall, the results of this analysis suggest that the RSQ is an effective tool for assessing respiratory
symptoms in patients with asthma and/or COPD. Symptoms such as shortness of breath, wheeze, cough
and chest tightness are characteristic of both asthma and COPD, and their diagnostic criteria overlap.
There is substantial interest in developing more specific classifications of obstructive lung disease and in
TABLE 4 Respiratory Symptoms Questionnaire (RSQ) differentiation of physician-assessed
severity categories
Asthma Asthma+COPD COPD Total
sample
Patients 510 510 510 1530
RSQ scores# by physician-assessed severity¶
Mild
Patients with non-missing data 188 90 122 400
Mean±SD 3.32±3.27 5.06±4.13 4.11±3.71 3.95±3.67
Moderate
Patients with non-missing data 186 223 150 559
Mean±SD 4.12±3.74 5.15±3.95 5.47±4.04 4.89±3.94
Severe
Patients with non-missing data 136 197 238 571
Mean±SD 6.43±3.92 8.54±4.31 7.37±4.30 7.55±4.29
RSQ differentiation by physician-assessed
severity¶
Standardised mean differences+
Mild versus moderate 0.23 0.02 0.35 0.25
Mild versus severe 0.87 0.82 0.79 0.89
Moderate versus severe 0.60 0.82 0.45 0.64
Group comparison
Mild versus moderate 0.1042 0.9840 0.0249 0.0017
Mild versus severe <0.0001 <0.0001 <0.0001 <0.0001
Moderate versus severe <0.0001 <0.0001 <0.0001 <0.0001
F-value 30.02 41.46 27.61 109.85
p-value <0.0001 <0.0001 <0.0001 <0.0001
Data are presented as n, unless otherwise stated. COPD: chronic obstructive pulmonary disease. #: range
0–16; ¶: for patients with asthma+COPD, physician-assessed severity was allocated as the higher of the
two severity categories assigned by the physician for their asthma and their COPD; +: Cohen’s d.
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identifying underlying mechanisms, independent of conventional diagnostic labels [18, 19]. It is therefore
essential to use the same tools for assessing respiratory symptoms across the whole spectrum of obstructive
lung disease rather than using diagnosis-specific questionnaires for asthma and for COPD. Very few such
tools are available. Both the ACT and E-RS: COPD diary focus on respiratory symptoms, but are
diagnosis-specific. Questions about respiratory symptoms are included in several health status
questionnaires such as the SGRQ and AQ20, but these tools are intended for assessing health status rather
than only symptoms; they are also longer, e.g. the SGRQ takes 10–15 min to complete [16]. Unlike these
tools, the RSQ is a diagnosis-agnostic tool that can assess respiratory symptoms consistently across the
broad spectrum of obstructive lung disease. As there are only four questions, it can be completed in
1–2 min; this may be particularly valuable in primary care settings, where visit time is limited.
In conclusion, the results of this analysis demonstrate that the RSQ is a valid, easy-to-administer
patient-reported tool for assessing and monitoring respiratory symptoms in patients with asthma and/or
COPD. The RSQ is an effective diagnosis-agnostic measure that can be used for monitoring
patient-reported respiratory symptoms in clinical practice, clinical trials and real-world studies. The RSQ
may also be a valuable tool in studies to further our understanding of obstructive lung disease beyond
conventional diagnostic labels or for patients in whom a diagnosis has not yet been made.
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